Fundz
New|Fundz now works inside Claude2 min

Timing. Relevance. Relationships.

Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.

Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.

Trusted by

OracleSnowflakeCloudflareLinkedInGoogleSalesforce
4.8/5 on G2· Since 2015

Novartis Enters Agreement Worth Up to $7.8 Billion with Abogen Biosciences for mRNA-based T Cell Engager Development.

Oct 02, 2026

Contract Type

agreement

SwitzerlandBiotechnologyHealth Carepharmaceuticals

Description

Novartis has formed an agreement with China's Abogen Biosciences involving an upfront payment of $575 million and potential milestone payments totaling up to $7.2 billion. This partnership focuses on developing ABO2203, an mRNA candidate aimed at improving T cell engager safety for patients with autoimmune diseases.

Company Information

Company

Novartis

Location

2 Fabrikstrasse

Switzerland

About

Novartis India Ltd is a subsidiary of Novartis AG, focusing on healthcare products for chronic conditions. The company has a diverse portfolio including diabetes, neurology, and cardiology therapies. It operates in the Indian pharmaceutical market with a robust revenue stream. Novartis India aims to provide innovative solutions in healthcare.

Related People

Shreeram
Senior decision-maker at this company
••••••••@••••••••

See Shreeram's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Novartis's next move

Learn about Strategic plan

Novartis signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.